Designer probiotics: a potential therapeutic for Clostridium difficile?

References

1. Corr S. C., Li Y., Riedel C. U., O'Toole P. W., Hill C., Gahan C. G. 2007; Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 104:7617–7621 [CrossRef]
   [Google Scholar]
2. Crogan N. L., Evans B. C. 2007; Clostridium difficile : an emerging epidemic in nursing homes. Geriatr Nurs 28:161–164 [CrossRef]
   [Google Scholar]
3. Gardiner G. E., Rea M. C., O'Riordan B., O'Connor P., Morgan M. S., Lawlor P. G., Lynch P. B., Cronin M., Ross R. P., Hill C. 2007; Fate of the two-component lantibiotic lacticin 3147 in the gastrointestinal tract. Appl Environ Microbiol 73:7103–7109 [CrossRef]
   [Google Scholar]
4. Hickson M., D'Souza A. L., Muthu N., Rogers T. R., Want S., Rajkumar C., Bulpitt C. J. 2007; Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335:80 [CrossRef]
   [Google Scholar]
5. Kuijper E. J., van Dissel J. T., Wilcox M. H. 2007; Clostridium difficile : changing epidemiology and new treatment options. Curr Opin Infect Dis 20:376–383
   [Google Scholar]
6. McFarland L. V. 2005; Alternative treatments for Clostridium difficile disease: what really works?. J Med Microbiol 54:101–111 [CrossRef]
   [Google Scholar]
7. Paton A. W., Morona R., Paton J. C. 2000; A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 6:265–270 [CrossRef]
   [Google Scholar]
8. Paton A. W., Morona R., Paton J. C. 2006; Designer probiotics for prevention of enteric infections. Nat Rev Microbiol 4:193–200 [CrossRef]
   [Google Scholar]
9. Rea M. C., Clayton E., O'Connor P. M., Shanahan F., Kiely B., Ross R. P., Hill C. 2007; Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J Med Microbiol 56:940–946 [CrossRef]
   [Google Scholar]
10. Sheehan V. M., Sleator R. D., Fitzgerald G. F., Hill C. 2006; Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Appl Environ Microbiol 72:2170–2177 [CrossRef]
    [Google Scholar]
11. Sheehan V. M., Sleator R. D., Hill C., Fitzgerald G. F. 2007; Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. Microbiology 153:3563–3571 [CrossRef]
    [Google Scholar]
12. Sleator R. D., Hill C. 2006; Patho-biotechnology: using bad bugs to do good things. Curr Opin Biotechnol 17:211–216 [CrossRef]
    [Google Scholar]
13. Sleator R. D., Hill C. 2007a; Improving probiotic function using a patho-biotechnology approach. Gene Ther Mol Biol 11:269–274
    [Google Scholar]
14. Sleator R. D., Hill C. 2007b; Patho-biotechnology; using bad bugs to make good bugs better. Sci Prog 90:1–14 [CrossRef]
    [Google Scholar]
15. Sleator R. D., Hill C. 2007c; Probiotics as therapeutics for the developing world. J Infect Developing Countries 1:7–12
    [Google Scholar]
16. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., Frost E., McDonald L. C. 2005; Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084 [CrossRef]
    [Google Scholar]